My wild guess is that that the problems arose with

My wild guess is that that the problems arose with the Prurisol CRO (cost increases, delays, etc.) whatever they may have been. A B-OM deal with 10M-20M upfront wouldn't have given us enough money to pay the CRO and advance anything else in the pipeline and stop the dilution machine. Including B for IBD indications likely allows the upfront to be 50M-100M+ which gives IPIX money for a couple years of operating expenses plus some trial advancement. Milestone payments from this deal will hopefully carry us to royalties without additional dilution.

I have been a proponent of the largest deal possible (preferred a buyout) and I am pleased to see the larger deal size. I hope this deal will be enough to get us uplisted and lock in the share count. Additionally, I think it's paramount that we get every share in the green ($5/share) as soon as possible even if it means giving up rights years down the line. Now that we're not doing a full buyout, I'm hoping we lock in a second deal on B or P (if results are good) ASAP. A high probability $5-10 is much preferable to an uncertain $50.